Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.65 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.65 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.65 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.65 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.61 |
| ▸ | PRKACA | P17612 | 2/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.61 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.61 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.61 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.61 |
| ▸ | PRKCG | P05129 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | LYN | P07948 | 1/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | PIM1 | P11309 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | FLT4 | P35916 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640317 | 0.93 | MAPK14 (0.75) | MAPK14MAPK11MAPK13MAPK12PRKD3 | |
| SCHEMBL1906575 | 0.83 | MAPK14 (0.88) | MAPK14MAPK11MAPK13MAPK12PRKD3 | |
| SCHEMBL1639811 | 0.82 | MAPK14 (0.58) | MAPK14MAPK11MAPK13MAPK12PRKD3 | |
| Vk-19911 SCHEMBL140202 | 0.79 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12PRKD3 | |
| SCHEMBL1902056 | 0.78 | MAPK14 (0.57) | MAPK14MAPK11MAPK13MAPK12PRKD3 | |
| SCHEMBL1639785 | 0.77 | CSNK1D (0.60) | MAPK14MAPK11MAPK13MAPK12PRKD3 | |
| SCHEMBL1639982 | 0.76 | MAPK14 (0.52) | MAPK14MAPK11MAPK13MAPK12PRKD3 | |
| SCHEMBL4585589 | 0.76 | MAPK14 (0.80) | MAPK14MAPK11MAPK13MAPK12PRKD3 | |
| Sb-220025 SCHEMBL173441 | 0.76 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12PRKD3 | |
| SCHEMBL7136557 | 0.76 | MAPK14 (0.77) | MAPK14MAPK11MAPK13MAPK12PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102686580-B | imidazole derivatives as casein kinase inhibitors | PFIZER | 2014-09-10 | — | — | CN | disclosed |
| EP-2493876-B1 | IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2493876-B1 | IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8518944-B2 | Compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518944-B2 | Compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518944-B2 | Compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2493876-A1 | IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS | Pfizer Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051858-A1 | IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS | PFIZER INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | PFIZER INC | 2011-04-28 | — | — | US | disclosed |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | PFIZER INC | 2011-04-28 | — | — | US | disclosed |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | PFIZER INC | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | CSNK1A1, CSNK1A1L, CSNK1G1 | MAPK14 169/4885MAPK11 295/4885MAPK13 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.